Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation.
Journal
Thrombosis and haemostasis
ISSN: 2567-689X
Titre abrégé: Thromb Haemost
Pays: Germany
ID NLM: 7608063
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
pubmed:
31
12
2022
medline:
10
2
2023
entrez:
30
12
2022
Statut:
ppublish
Résumé
Antiplatelet therapy is considered essential for secondary prevention of ischemic heart disease. After percutaneous coronary intervention (PCI), temporary dual antiplatelet therapy (DAPT), a combination consisting of aspirin and an oral P2Y12 receptor blocker, is recommended. In the long term, this strategy results in more bleeding than antiplatelet therapy with aspirin alone. Therefore, to reduce bleeding, an increasing trend has been to keep DAPT as short as clinically acceptable, after which aspirin monotherapy is continued. Another option to diminish bleeding is to discontinue aspirin at the moment of DAPT cessation after PCI, and to continue on P2Y12 blocker monotherapy. This survey reviews the evidence on P2Y12 blocker monotherapy. Some clinical guidance will be provided on when and in whom P2Y12 inhibitor monotherapy may be applied after DAPT cessation following PCI.
Identifiants
pubmed: 36584699
doi: 10.1055/s-0042-1755330
doi:
Substances chimiques
Aspirin
R16CO5Y76E
Platelet Aggregation Inhibitors
0
Purinergic P2Y Receptor Antagonists
0
P2RY12 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
159-165Informations de copyright
Thieme. All rights reserved.
Déclaration de conflit d'intérêts
F.W.A.V. has received honoraria for consulting and presentations from AstraZeneca, Bayer Healthcare, and Daiichi-Sankyo. K.H. has received honoraria for consulting and lectures from AstraZeneca, Chiesi, Daiichi Sankyo, and Sanofi-Aventis. P.C. has received lecture fees, performed consulting, or been involved in research contracts outside the context of the present work: Abbott, AstraZeneca, Aventis, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Eli-Lilly, Evolva, Fiberx, Janssen, Merck, Myogen, Medtronic, Mitsubishi Pharma, The Medicines Company, Nycomed, Organon, Pfizer, Pharmacia, Regado, Sanofi, Searle, Servier, ViFor Pharma. J.-P.C. does not report any conflict of interest. T.C. has received consulting and lectures fees from Abbott, Boston Scientific, Edwards, and Medtronic. F.A. reports honoraria for consulting or lectures from Amgen, AstraZeneca, Bayer, BMS/Pfizer, and Daiichi Sankyo.